GoldenBiotech: Leading in new drug and health supplements –Brilliant results in lung cancer, pancreatic cancer and Alzheimer's.

2019-11-26

Golden Biotechnology Corp. is a leading biotech company that develops and produces new drugs and evidence-based helthy food supplements. A variety of cancer and chronic disease research milestone achieved: In 2015, the US FDA granted 3 orphan drug designations for its new drug: Antroquinonol(Hocena) in the treatment for pancreatic cancer, acute myeloid leukemia(AML) and HCC (liver cancer). In 2019, the brilliant clinical results of its phase II clinical trial in USA and Taiwan for NSCLC( non-small cell lung cancer ) has been published in the meeting abstract at ASCO annual conference. The Phase II studies of orally administrated Antroquinonol was a monotherapy treatment for those patients with stage 4 non-small cell lung cancer (NSCLC) who have failed at least two lines of anti-cancer therapy befor joining the trial. The overall disease control rate(DCR) was 72.7%, with 100% in KRAS negative and 50% in KRAS positive. The mOS(median overall survival) reached 47.3 weeks.No systemic toxicities were observed.The monotherapy of Antroquinonol brought up higher disease control rates and longer progression-free survival (PFS)and overall survival, compared with historical data. In November 2019, the US FDA approved another phase 2 clinical trial of Antroquinonol(HOCENA) for first-line treatment combined with current standard chemotherapy drugs for Stage 4 non-small cell lung cancer (NSCLC) patients.

In November 2019, GoldenBiotech’s Antroquinonol (HOCENA) has also made a major breakthrough in pancreatic cancer clinical trial. The trial in USA and Taiwan for Phase 1/2 clinical study of Antroquinonol® in combination with two chemotherapy drugs : gemcitabine (Gemzar®) and nab-paclitaxel (Abraxane®) as first line treatment for patients with metastatic pancreatic cancer. According to current on-going trial data revealed better disease control than that of current approved two combined chemotherapy drugs. The patient's mOS calculated in November 2019 has already reached 6.7 months, and with patients have survived for more than 19 months. From the current data trend observation, comparing other chemotherapy combined therapy, its mOS data will surpass that of the existing standard therapy drugs.

Furthermore, Antroquinonol® was awarded in pharmaceutical sector of Advance Queensland – Johnson & Johnson Innovation QuickFire Challenge for its potential as a treatment for Alzheimer’s disease in 2016. The pre-clinical animal study of Antroquinonol for Alzheimer's disease in Queensland University of Technology in Australia has shown the obvious improvements in prevention and treatment of Alizheimer’s disease. With significant effects on the inhibition of the aggregation of Amyloid beta, Tau protein tangle and anti-inflammation, Antroquinonol also exhibited improving the learning capability in the testing animals. For non-oncology research areas, Antroquinonol® has also been approved for its efficacy in hyperlipidemia which was unblinded in 2018 for lowering the triglyceride(TG) and LDL-C as well improving the fatty liver testing parameters.

Welcome to our booth at S931 in the Biotech and Pharma area, for our new developments and further collaborations with Golden Biotechnology Corp.

》Cooperation projects and needs：1. New drug cooperation development investment authorization.... Welcome cooperation with GoldenBiotech in new drugs development, Licensing....; 2.Regional Distribution of GoldenBiotech’s healthy food supplement products.; 3.Cancer Drug, Oncology, NSCLC, Pancreatic Cancer, Alzheimer's, NASH, AML, Hyperlipid.; 4.Health supplements for liver ,prostate,autoimmune,hyperlipid, Cancer adjuvant